MF研究者総覧

研究者データベース

詳細
researchmap個人ページ
Last Updated :2024/11/09

研究者情報

マスター

アカウント（マスター）

  • 氏名

    金平　孝博(カネヒラ　タカヒロ), カネヒラ　タカヒロ

所属（マスター）

  • 北海道大学病院　中央診療施設等

所属（マスター）

  • 北海道大学病院　中央診療施設等

独自項目

syllabus

  • 2021, 臨床医学物理学実習（品質管理）, Clinical Medical Physics Training (Quality Assurance), 博士後期課程, 医理工学院, 放射線防護、放射線治療装置、位置照合装置、治療計画、QA Radiation protection, exteranal beam treatment units, position matching device, treatment planning system, QA
  • 2021, 臨床医学物理学実習（治療計画）, Clinical Medical Physics Training (Treatment Planning), 博士後期課程, 医理工学院, 照射録、X線、電子線、小線源治療、品質管理、治療計画 Treatment record, x-ray, electron beam, proton beam, brachytherapy, quality accurance, treatment planning
  • 2021, 臨床医学物理学実習（陽子線・画像誘導）, Clinical Medical Physics Training (Proton/Image-guided Radiation Therapy), 博士後期課程, 医理工学院, 放射線治療装置、位置照合装置、治療計画、CT、陽子線治療 radiotherapy device, position matching device, planning system, CT, proton treatment

researchmap

プロフィール情報

学位

  • 博士(医学)（2017年03月 北海道大学）

プロフィール情報

  • 姓

    金平, カネヒラ

  • 名

    孝博, タカヒロ

  • ID各種

    202001016221054288

業績リスト

研究キーワード

  • 適応放射線治療   肺がん   リンパ球減少症   正常組織有害事象発生確率モデル   放射線治療   

研究分野

  • ライフサイエンス / 放射線科学 / 医学物理, 放射線治療

経歴

  • 2020年03月 - 現在 北海道大学病院 医学物理部 助教
  • 2017年02月 - 2029年02月 オランダ癌センター 放射線腫瘍分野 博士研究員

学歴

  • 2013年 - 2017年   北海道大学   大学院医学研究科   放射線医学分野
  • 2011年09月 - 2012年09月   アバディーン大学   生体医学物理・生体工学学科学部
  • 2007年04月 - 2011年03月   北海道大学   医学部保健学科   放射線技術科学専攻

委員歴

  • 2024年04月 - 現在   日本医学物理学会   代議員
  • 2024年04月 - 現在   日本医学物理学会   国際交流委員

論文

  • Takaaki Yoshimura, Keigo Kondo, Takayuki Hashimoto, Kentaro Nishioka, Takashi Mori, Takahiro Kanehira, Taeko Matsuura, Seishin Takao, Hiroshi Tamura, Takuya Matsumoto, Kenneth Sutherland, Hidefumi Aoyama
    Journal of radiation research 2024年09月15日 
    In proton craniospinal irradiation (CSI) for skeletally immature pediatric patients, a treatment plan should be developed to ensure that the dose is uniformly delivered to all vertebrae, considering the effects on bone growth balance. The technical (t) clinical target volume (CTV) is conventionally set by manually expanding the CTV from the entire intracranial space and thecal sac, based on the physician's experience. However, there are differences in contouring methods among physicians. Therefore, we aimed to propose a new geometric target margin strategy. Nine pediatric patients with medulloblastoma who underwent proton CSI were enrolled. We measured the following water equivalent lengths for each vertebra in each patient: body surface to the dorsal spinal canal, vertebral limbus, ventral spinal canal and spinous processes. A simulated tCTV (stCTV) was created by assigning geometric margins to the spinal canal using the measurement results such that the vertebral limb and dose distribution coincided with a margin assigned to account for the uncertainty of the proton beam range. The stCTV with a growth factor (correlation between body surface area and age) and tCTV were compared and evaluated. The median values of each index for cervical, thoracic and lumber spine were: the Hausdorff distance, 9.14, 9.84 and 9.77 mm; mean distance-to-agreement, 3.26, 2.65 and 2.64 mm; Dice coefficient, 0.84, 0.81 and 0.82 and Jaccard coefficient, 0.50, 0.60 and 0.62, respectively. The geometric target margin setting method used in this study was useful for creating an stCTV to ensure consistent and uniform planning.
  • Naoki Miyamoto, Norio Katoh, Takahiro Kanehira, Kohei Yokokawa, Ryusuke Suzuki, Yusuke Uchinami, Hiroshi Taguchi, Daisuke Abo, Hidefumi Aoyama
    Physics and imaging in radiation oncology 31 100623 - 100623 2024年07月 [査読有り]
     
    Real-time tumor-tracking volumetric modulated arc therapy (RT-VMAT) enabling beam-gating based on continuous X-ray tracking of the three-dimensional position of internal markers is relevant for moving tumors. Dose-volume characteristics and treatment time were evaluated in ten consecutive patients who underwent liver stereotactic body radiation therapy with RT-VMAT. Target dose conformity and sparing of the stomach and the intestine were improved comparing RT-VMAT with RT-3D conformal radiotherapy. The mean treatment time for each fraction was less than 10 min. RT-VMAT could be effective, especially for targets located adjacent to organs at risk.
  • Yuki Saito, Ryusuke Suzuki, Naoki Miyamoto, Kenneth Lee Sutherland, Takahiro Kanehira, Masaya Tamura, Takashi Mori, Kentaro Nishioka, Takayuki Hashimoto, Hidefumi Aoyama
    Journal of Applied Clinical Medical Physics 2024年04月 [査読有り][通常論文]
  • Takaaki Yoshimura, Ryota Yamada, Rumiko Kinoshita, Taeko Matsuura, Takahiro Kanehira, Hiroshi Tamura, Kentaro Nishioka, Koichi Yasuda, Hiroshi Taguchi, Norio Katoh, Keiji Kobashi, Takayuki Hashimoto, Hidefumi Aoyama
    Journal of radiation research 2024年03月17日 [査読有り]
     
    This retrospective treatment-planning study was conducted to determine whether intensity-modulated proton therapy with robust optimization (ro-IMPT) reduces the risk of acute hematologic toxicity (H-T) and acute and late gastrointestinal toxicity (GI-T) in postoperative whole pelvic radiotherapy for gynecologic malignancies when compared with three-dimensional conformal radiation therapy (3D-CRT), intensity-modulated X-ray (IMXT) and single-field optimization proton beam (SFO-PBT) therapies. All plans were created for 13 gynecologic-malignancy patients. The prescribed dose was 45 GyE in 25 fractions for 95% planning target volume in 3D-CRT, IMXT and SFO-PBT plans and for 99% clinical target volume (CTV) in ro-IMPT plans. The normal tissue complication probability (NTCP) of each toxicity was used as an in silico surrogate marker. Median estimated NTCP values for acute H-T and acute and late GI-T were 0.20, 0.94 and 0.58 × 10-1 in 3D-CRT; 0.19, 0.65 and 0.24 × 10-1 in IMXT; 0.04, 0.74 and 0.19 × 10-1 in SFO-PBT; and 0.06, 0.66 and 0.15 × 10-1 in ro-IMPT, respectively. Compared with 3D-CRT and IMXT plans, the ro-IMPT plan demonstrated significant reduction in acute H-T and late GI-T. The risk of acute GI-T in ro-IMPT plan is equivalent with IMXT plan. The ro-IMPT plan demonstrated potential clinical benefits for reducing the risk of acute H-T and late GI-T in the treatment of gynecologic malignances by reducing the dose to the bone marrow and bowel bag while maintaining adequate dose coverage to the CTV. Our results indicated that ro-IMPT may reduce acute H-T and late GI-T risk with potentially improving outcomes for postoperative gynecologic-malignancy patients with concurrent chemotherapy.
  • Yusuke Uchinami, Takahiro Kanehira, Keiji Nakazato, Yoshihiro Fujita, Fuki Koizumi, Shuhei Takahashi, Manami Otsuka, Koichi Yasuda, Hiroshi Taguchi, Kentaro Nishioka, Naoki Miyamoto, Kohei Yokokawa, Ryusuke Suzuki, Keiji Kobashi, Keita Takahashi, Norio Katoh, Hidefumi Aoyama
    BJR|Open 5 1 2023年08月 [査読有り]
     
    Objectives: We aimed to investigate whether daily computed tomography (CT) images could predict the daily gastroduodenal, small intestine, and large intestine doses of stereotactic body radiation therapy (SBRT) for pancreatic cancer based on the shortest distance between the gross tumor volume (GTV) and gastrointestinal (GI) tract. Methods: Twelve patients with pancreatic cancer received SBRT of 40 Gy in five fractions. We recalculated the reference clinical SBRT plan (PLANref) using daily CT images and calculated the shortest distance from the GTV to each GI tract. The maximum dose delivered to 0.5 cc (D0.5cc) was evaluated for each planning at-risk volume of the GI tract. Spearman’s correlation test was used to determine the association between the daily change in the shortest distance (Δshortest distance) and the ratio of ΔD0.5cc dose to D0.5cc dose in PLANref (ΔD0.5cc/PLANref) for quantitative analysis. Results: The median shortest distance in PLANref was 0 mm in the gastroduodenum (interquartile range, 0–2.7), 16.7 mm in the small intestine (10.0–23.7), and 16.7 mm in the large intestine (8.3–28.1 mm). The D0.5cc of PLANref in the gastroduodenum was >30 Gy in all patients, with 10 (83.3%) having the highest dose. A significant association was found between the Δshortest distance and ΔD0.5cc/ PLANref in the small or large intestine (p < 0.001) but not in the gastroduodenum (p = 0.404). Conclusions: The gastroduodenum had a higher D0.5cc and predicting the daily dose was difficult. Daily dose calculations of the GI tract are recommended for safe SBRT. Advances in knowledge: This study aimed to predict the daily doses in SBRT for pancreatic cancer from the shortest distance between the GTV and the gastrointestinal tract. Daily changes in the shortest distance can predict the daily dose to the small or large intestines, but not to the gastroduodenum.
  • Yusuke Uchinami, Takahiro Kanehira, Yoshihiro Fujita, Naoki Miyamoto, Kohei Yokokawa, Fuki Koizumi, Motoyasu Shido, Shuhei Takahashi, Manami Otsuka, Koichi Yasuda, Hiroshi Taguchi, Keiji Nakazato, Keiji Kobashi, Norio Katoh, Hidefumi Aoyama
    Clinical and Translational Radiation Oncology 39 100576 - 100576 2023年03月 [査読有り]
  • Yusuke Uchinami, Norio Katoh, Daisuke Abo, Ryo Morita, Hiroshi Taguchi, Yoshihiro Fujita, Takahiro Kanehira, Ryusuke Suzuki, Naoki Miyamoto, Seishin Takao, Taeko Matsuura, Takuya Sho, Koji Ogawa, Tatsuya Orimo, Tatsuhiko Kakisaka, Keiji Kobashi, Hidefumi Aoyama
    The British journal of radiology 96 1144 20220720 - 20220720 2023年01月12日 [査読有り]
     
    OBJECTIVES: In a previous study of hepatic toxicity, the following three factors were identified to predict the benefits of proton beam therapy (PBT) for hepatocellular carcinomas (HCC) with a maximum diameter of ≤5 cm and Child-pugh grade A (CP-A): number of tumors (one vs ≥2), the location of tumors (hepatic hilum or others), and the sum of the diameters of lesions. The aim of this study is to analyze the association between these three factors and hepatic toxicity. METHODS: We retrospectively reviewed patients of CP-A treated with PBT or photon stereotactic body radiotherapy (X-ray radiotherapy, XRT) for HCC ≤5 cm. For normal liver dose, the V5, V10, V20 (volumes receiving 5, 10, and 20 Gy at least), and the mean dose was evaluated. The albumin-bilirubin (ALBI) and CP score changes from the baseline were evaluated at 3 and 6 months after treatment. RESULTS: In 89 patients (XRT: 48, PBT: 41), those with two or three (2-3) predictive factors were higher normal liver doses than with zero or one (0-1) factor. In the PBT group, the ALBI score worsened more in patients with 2-3 factors than those with 0-1 factor, at 3 months (median 0.26 vs 0.02, p = 0.032) and at 6 months (median: 0.35 vs 0.10, p = 0.009). The ALBI score change in the XRT group and CP score change in either modality were not significantly different in the number of predictive factors. CONCLUSIONS: The predictive factor numbers predicted the ALBI score change in PBT but not in XRT. ADVANCES IN KNOWLEDGE: This study suggest that the number of predictive factors previously identified (0-1 vs 2-3) were significantly associated with dosimetric parameters of the normal liver in both modalities. In the proton group, the number of predictive factors was associated with a worsening ALBI score at 3 and 6 months, but these associations were not found in the photon SBRT group.
  • Koichi Miyazaki, Yusuke Fujii, Takahiro Yamada, Takahiro Kanehira, Naoki Miyamoto, Taeko Matsuura, Koichi Yasuda, Yusuke Uchinami, Manami Otsuka, Hidefumi Aoyama, Seishin Takao
    Medical physics 50 2 675 - 687 2022年12月11日 [査読有り]
     
    BACKGROUND: Online adaptation during intensity-modulated proton therapy (IMPT) can minimize the effect of inter-fractional anatomical changes, but remains challenging because of the complex workflow. One approach for fast and automated online IMPT adaptation is dose restoration, which restores the initial dose distribution on the updated anatomy. However, this method may fail in cases where tumor deformation or position changes occur. PURPOSE: To develop a fast and robust IMPT online adaptation method named "deformed dose restoration (DDR)" that can adjust for inter-fractional tumor deformation and position changes. METHODS: THE DDR METHOD COMPRISES TWO STEPS: : (1) calculation of the deformed dose distribution, and (2) restoration of the deformed dose distribution. First, the deformable image registration (DIR) between the initial clinical target volume (CTV) and the new CTV were performed to calculate the vector field. To ensure robustness for setup and range uncertainty and the ability to restore the deformed dose distribution, an expanded CTV-based registration to maintain the dose gradient outside the CTV was developed. The deformed dose distribution was obtained by applying the vector field to the initial dose distribution. Then, the voxel-by-voxel dose difference optimization was performed to calculate beam parameters that restore the deformed dose distribution on the updated anatomy. The optimization function was the sum of total dose differences and dose differences of each field to restore the initial dose overlap of each field. This method only requires target contouring, which eliminates the need for organs at risk (OARs) contouring. Six clinical cases wherein the tumor deformation and/or position changed on repeated CTs were selected. DDR feasibility was evaluated by comparing the results with those from three other strategies, namely, not adapted (continuing the initial plan), adapted by previous dose restoration, and fully optimized. RESULTS: In all cases, continuing the initial plan was largely distorted on the repeated CTs and the dose-volume histogram (DVH) metrics for the target were reduced due to the tumor deformation or position changes. On the other hand, DDR improved DVH metrics for the target to the same level as the initial dose distribution. Dose increase was seen for some OARs because tumor growth had reduced the relative distance between CTVs and OARs. Robustness evaluation for setup and range uncertainty (3 mm/3.5%) showed that deviation in DVH-bandwidth for CTV D95% from the initial plan was 0.4 ± 0.5% (Mean ± S.D.) for DDR. The calculation time was 8.1 ± 6.4 min. CONCLUSIONS: An online adaptation algorithm was developed that improved the treatment quality for inter-fractional anatomical changes and retained robustness for intra-fractional setup and range uncertainty. The main advantage of this method is that it only requires target contouring alone and saves the time for OARs contouring. The fast and robust adaptation method for tumor deformation and position changes described here can reduce the need for offline adaptation and improve treatment efficiency. This article is protected by copyright. All rights reserved.
  • 木下 留美子, 檜垣 朔, 藤田 祥博, 森 崇, 西岡 健太郎, 橋本 孝之, 青山 英史, 押野 智博, 高橋 将人, 加藤 扶美, 金平 孝博
    北海道外科雑誌 67 2 162 - 163 北海道外科学会 2022年12月
  • Yusuke Uchinami, Norio Katoh, Ryusuke Suzuki, Takahiro Kanehira, Masaya Tamura, Seishin Takao, Taeko Matsuura, Naoki Miyamoto, Yoshihiro Fujita, Fuki Koizumi, Hiroshi Taguchi, Koichi Yasuda, Kentaro Nishioka, Isao Yokota, Keiji Kobashi, Hidefumi Aoyama
    Clinical and Translational Radiation Oncology 35 70 - 75 2022年07月 [査読有り]
  • Takahiro Kanehira, Simon van Kranen, Tomas Jansen, Olga Hamming-Vrieze, Abrahim Al-Mamgani, Jan-Jakob Sonke
    Radiotherapy and Oncology 164 209 - 215 2021年11月 [査読有り]
  • Takaaki Yoshimura, Kentaro Nishioka, Takayuki Hashimoto, Kazuya Seki, Shouki Kogame, Sodai Tanaka, Takahiro Kanehira, Masaya Tamura, Seishin Takao, Taeko Matsuura, Keiji Kobashi, Fumi Kato, Hidefumi Aoyama, Shinichi Shimizu
    Physics and Imaging in Radiation Oncology 20 23 - 29 2021年10月 [査読有り]
     
    BACKGROUND AND PURPOSE: Urethra-sparing radiation therapy for localized prostate cancer can reduce the risk of radiation-induced genitourinary toxicity by intentionally underdosing the periurethral transitional zone. We aimed to compare the clinical impact of a urethra-sparing intensity-modulated proton therapy (US-IMPT) plan with that of conventional clinical plans without urethral dose reduction. MATERIALS AND METHODS: This study included 13 patients who had undergone proton beam therapy. The prescribed dose was 63 GyE in 21 fractions for 99% of the clinical target volume. To compare the clinical impact of the US-IMPT plan with that of the conventional clinical plan, tumor control probability (TCP) and normal tissue complication probability (NTCP) were calculated with a generalized equivalent uniform dose-based Lyman-Kutcher model using dose volume histograms. The endpoints of these model parameters for the rectum, bladder, and urethra were fistula, contraction, and urethral stricture, respectively. RESULTS: The mean NTCP value for the urethra in US-IMPT was significantly lower than that in the conventional clinical plan (0.6% vs. 1.2%, p < 0.05). There were no statistically significant differences between the conventional and US-IMPT plans regarding the mean minimum dose for the urethra with a 3-mm margin, TCP value, and NTCP value for the rectum and bladder. Additionally, the target dose coverage of all plans in the robustness analysis was within the clinically acceptable range. CONCLUSIONS: Compared with the conventional clinically applied plans, US-IMPT plans have potential clinical advantages and may reduce the risk of genitourinary toxicities, while maintaining the same TCP and NTCP in the rectum and bladder.
  • Takahiro Kanehira, Stina Svensson, Simon van Kranen, Jan Jakob Sonke
    Physics and Imaging in Radiation Oncology 14 39 - 42 2020年04月 [査読有り]
     
    © 2020 The Author(s) Accurate estimation of the daily radiotherapy dose is challenging in a multi-institutional collaboration when the institution specific treatment planning system (TPS) is not available. We developed and evaluated a method to tackle this problem. Residual errors in daily estimations were minimized with single correction based on the planned dose. For nine patients, medians of the absolute estimation errors for targets and OARs were less than 0.2 Gy (Dmean), 0.3 Gy (D1), and 0.1 Gy (D99). In general, mimicking errors were significantly smaller than dose differences caused by anatomical changes. The demonstrated accuracy may facilitate dose accumulation in a multi-institutional/multi-vendor setting.
  • Takahiro Kanehira, Taeko Matsuura, Seishin Takao, Yuka Matsuzaki, Yusuke Fujii, Takaaki Fujii, Yoichi M. Ito, Naoki Miyamoto, Tetsuya Inoue, Norio Katoh, Shinichi Shimizu, Kikuo Umegaki, Hiroki Shirato
    International Journal of Radiation Oncology Biology Physics 97 1 173 - 181 2017年01月01日 [査読有り]
     
    © 2016 Elsevier Inc. Purpose To investigate the effectiveness of real-time-image gated proton beam therapy for lung tumors and to establish a suitable size for the gating window (GW). Methods and Materials A proton beam gated by a fiducial marker entering a preassigned GW (as monitored by 2 fluoroscopy units) was used with 7 lung cancer patients. Seven treatment plans were generated: real-time-image gated proton beam therapy with GW sizes of ±1, 2, 3, 4, 5, and 8 mm and free-breathing proton therapy. The prescribed dose was 70 Gy (relative biological effectiveness)/10 fractions to 99% of the target. Each of the 3-dimensional marker positions in the time series was associated with the appropriate 4-dimensional computed tomography phase. The 4-dimensional dose calculations were performed. The dose distribution in each respiratory phase was deformed into the end-exhale computed tomography image. The D99 and D5 to D95 of the clinical target volume scaled by the prescribed dose with criteria of D99 >95% and D5 to D95 <5%, V20 for the normal lung, and treatment times were evaluated. Results Gating windows ≤ ±2 mm fulfilled the CTV criteria for all patients (whereas the criteria were not always met for GWs ≥ ±3 mm) and gave an average reduction in V20 of more than 17.2% relative to free-breathing proton therapy (whereas GWs ≥ ±4 mm resulted in similar or increased V20). The average (maximum) irradiation times were 384 seconds (818 seconds) for the ±1-mm GW, but less than 226 seconds (292 seconds) for the ±2-mm GW. The maximum increased considerably at ±1-mm GW. Conclusion Real-time-image gated proton beam therapy with a GW of ±2 mm was demonstrated to be suitable, providing good dose distribution without greatly extending treatment time.

MISC

講演・口頭発表等

  • Comparing predictors of radiation-induced lymphopenia in various timeframes in NSCLC radiotherapy
    Takahiro Kanehira, Hiroshi Taguchi, Jun Sakakibara-Konishi, Norio Katoh, Yusuke Uchinami, Keiji Kobashi, Takayuki Hashimoto, Hidefumi Aoyama
    欧州放射線腫瘍学会
  • 肺癌に対する化学放射線治療中のリンパ球減少が全生存率に及ぼす影響
    田口大志, 金平孝博, 宮崎, 高柳泰輔, 青山英史
    日本放射線腫瘍学会第36回学術大会 2023年11月
  • 肺癌に対する化学放射線治療中のリンパ球数予測モデルの開発
    宮崎康一, 高柳泰輔, 金平孝博, 田口大志, 青山英史
    日本放射線腫瘍学会第36回学術大会 2023年11月
  • Effect of early fractional lymphocyte loss on lymphopenia probability models for NSCLC
    T. Kanehira, H. Taguchi, N. Katoh, Y. Uchinami, T. Yoshimura, M. Tamura, R. Suzuki, T. Hashimoto, H. Aoyama
    欧州放射線腫瘍学会 2023年
  • プランライブラリを用いた膵癌定位放射線治療における日々の線量評価
    金平 孝博, 加藤 徳雄, 打浪 雄介, 宮﨑 智彦, 田口 大志, 横川 航平, 鈴木 隆介, 宮本 直樹, 青山 英史
    第37回高精度放射線外部照射部会学術大会 2023年03月
  • Comparison of dose accumulation based on CBCT and CT for lung cancer patients
    T. Kanehira, S.R. van Kranen, W.V. Vogel, J. Sonke
    欧州放射線腫瘍学会
  • Unsupervised deep learning for fast and accurate CBCT to CT deformable image registration
    S.R. Van Kranen, T. Kanehira, R. Rozendaal, J. Sonke
    欧州放射線腫瘍学会
  • Uncertainty estimation of dose accumulation with deformable image registration in head and neck region
    T. Kanehira, S. Kranen, J. Sonke
    欧州放射線腫瘍学会
  • Comparison of NTCP models between using planned and actual delivered dose for head and neck cancer
    T. Kanehira, S.R. Van Kranen, O. Hamming-Vrieze, T. Janssen, J.J. Sonke
    欧州放射線腫瘍学会
  • Simulation Study of Real-Time-Image Gating On Spot Scanning Proton Therapy for Lung Tumors
    T. Kanehira, T. Matsuura, S. Takao, Y. Matsuzaki, Y. Fujii, T. Fujii, N. Miyamoto, T. Inoue, N. Katoh, S. Shimizu, K. Umegaki, H. Shirato
    米国医学物理学会

担当経験のある科目（授業）

  • 臨床医学物理学実習（治療計画）北海道大学大学院医理工学院
  • 基礎放射線治療物理学北海道大学大学院医理工学院
  • 臨床医学物理学実習（品質管理）北海道大学大学院医学研究科
  • Medical Physics School

所属学協会

  • 日本医学物理学会   

共同研究・競争的資金等の研究課題


Copyright © MEDIA FUSION Co.,Ltd. All rights reserved.